CAMBRIDGE, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S. Patent No. 9,340,830. Under the terms of the settlement, the lawsuit and counterclaims, as well as challenges to the patent in inter partes review, have been dismissed. Financial terms and other specifics of the settlement were not disclosed.
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI)
is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding of
the genomic changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling assays to
identify the molecular alterations in a patient's cancer and match them
with relevant targeted therapies, immunotherapies and clinical trials.
Foundation Medicine’s molecular information platform aims to improve
day-to-day care for patients by serving the needs of clinicians,
academic researchers and drug developers to help advance the science of
molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).
About Guardant Health, Inc.
Guardant Health is a leading
precision oncology company focused on helping conquer cancer globally
through use of its proprietary blood tests, vast data sets and advanced
analytics. Its Guardant Health Oncology Platform is designed to leverage
its capabilities in technology, clinical development, regulatory and
reimbursement to drive commercial adoption, improve patient clinical
outcomes and lower healthcare costs. In pursuit of its goal to manage
cancer across all stages of the disease, Guardant Health has launched
multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for
advanced stage cancer patients, which fuel its development programs for
recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since
its launch in 2014, Guardant360 has become the world's market-leading
comprehensive liquid biopsy test and has been used by more than 5,000
oncologists, over 40 biopharmaceutical companies and all 27 of the
National Comprehensive Cancer Network Centers. Learn more at www.guardanthealth.com.
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
